宜明昂科生物医药技术（上海）股份有限公司（宜明昂科-B）于2026年6月8日在香港联交所回购H股股份，共回购26.58万股，占该次回购前已发行股份（不含库藏股）总数的约0.0632%。每股回购价格介乎每股3.04港元至3.27港元，合计支付约82.78万港元。回购完成后，公司已发行股份总数维持4.20亿股，其中外部流通股为4.20亿股，库藏股26.58万股。根据股东于2026年5月28日通过的回购授权，公司可回购的股份总数为4315.08万股，本次回购数量约占授权总额的0.0616%。
公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由执行董事、联席公司秘书关梅签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.